{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-065826","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2026-10-14T12:35:20+00:00","discovered_at":"2026-10-14T12:40:00.282566+00:00","generated_at":"2026-10-14T12:40:06.083331+00:00","sec_items":["3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vir Bio, Gilead sign solid-tumor TCE deal: $90M upfront, up to $1.74B milestones","bullets":["Gilead to pay $90M upfront ($65M cash plus $25M equity at a 30% premium) and up to $45M in near-term preclinical milestones, totaling up to $135M.","Vir eligible for up to $1.74B in development, regulatory and commercial milestones plus tiered high single-digit to low double-digit royalties on net sales.","Deal covers three novel PRO-XTEN dual-masked T-cell engager candidates targeting selected solid tumor-associated antigens, with Gilead holding an exclusive license.","Gilead to buy 1,765,486 VIR shares at $14.16/share (~$25M) under a Stock Purchase Agreement with 1-year standstill, voting and lockup provisions.","Vir handles discovery, design and optimization; Gilead leads development, manufacturing and commercialization. Vir's second PRO-XTEN collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-065826","json":"https://secwatch.observer/filing/0001628280-26-065826.json","markdown":"https://secwatch.observer/filing/0001628280-26-065826.md","text":"https://secwatch.observer/filing/0001628280-26-065826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026065826/0001628280-26-065826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026065826/vir-20261009.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-14T12:40:06.083331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}